FDA Extends Approval for Alirocumab to Lower LDL-C in Pediatric Patients with HeFH
Addressing an Unmet Need in Pediatric Patients with HeFH Heterozygous familial hypercholesterolemia (HeFH) affects about 1 in 313 people—characterized by dangerously high low-density lipoprotein cholesterol (LDL-C) levels. Untreated, it can trigger early heart disease. Detecting and treating it early in pediatric patients can prevent heart problems later. American College of Cardiology/American Heart Association guidelines define acceptable LDL-C […]
Heart Health Month: Cardiac Dysfunction in Children with COVID-19
With significant reported morbidity in adult patients and lesser impact on children, the COVID-19 virus continues to present a clinical challenge as its pathophysiology and presentation vary greatly. Cardiac dysfunction has been observed in adult cases of infection while the majority of pediatric patients have experienced minimal or mild symptoms. A range of cardiovascular complications […]
Childhood Type 2 Diabetes Accelerates Disease Complications
Previously referred to as “adult-onset diabetes”, type 2 diabetes (T2D) is most commonly associated with adult patients. However, due to continuously climbing obesity rates and decreased levels of physical activity, the prevalence of type 2 diabetes cases in youth is on the rise. Children and adolescents diagnosed with the condition are at risk of developing […]
